Diabetes Center Facts
- A team of UCSF investigators cloned the gene that produces human insulin in 1979; our clinical researchers coordinated the first multi-center clinical trial of human insulin in the 1980s.
- In 1981, UCSF co-discovered embryonic stem cells that are widely believed to have benefits for diabetes and numerous other diseases.
- UCSF was one of the first institutions to demonstrate that elevated blood sugar levels caused complications, helping to pioneer the intensive glucose control strategies now utilized throughout the world.
- UCSF is home to the Immune Tolerance Network (ITN), the international consortium of researchers working together to establish new treatments for diseases of the immune system including type 1 diabetes.
- An experimental antibody developed by former Diabetes Center Director and current UCSF Executive Vice Chancellor and Provost Dr. Jeffrey Bluestone, anti-CD3, was embraced by private industry in the fall of 2007; it is the furthest that an exclusively type 1 therapy has progressed in drug development and commercialization. Currently, anti-CD3 is being used in a type 1 prevention trial.
- Our classified cleanrooms for the human islet production core and cell therapy product core is one of the few FDA registered “Good Manufacturing Process” facilities in the US. The facility adheres to a robust quality program that supports current IND applications for human islets and expanded Tregs. For more information regarding the UCSF HICTF and GMP Facility Quality Program or QA Plan necessary for human clinical product manufacturing, please see the following link.
- Three scientists in the Diabetes Center are members of the National Academy of Sciences, one of America's highest scientific honors reserved only for the most accomplished researchers.
- The Diabetes Teaching Center, founded in 1978, is one of the country's oldest diabetes education programs, and remains among the most innovative.
- Over 25% of all hospital patients at the UCSF Medical Center have diabetes.